Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma
NCT05006534
·
clinicaltrials.gov ↗
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Relapsed Non Hodgkin Lymphoma
Refractory Lymphoma
Sponsor
National Taiwan University Hospital